Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer.

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer.

KRAS mutations occur in 35-45% of metastatic colorectal cancers (mCRC) and preclude responsiveness to EGFR-targeted therapy with cetuximab or panitumumab. However, less than 20% patients displaying wild-type KRAS tumors achieve objective response. Alterations in other effectors downstream of the EGF...

Full description

Bibliographic Details
Main Authors: Andrea Sartore-Bianchi, Federica Di Nicolantonio, Michele Nichelatti, Francesca Molinari, Sara De Dosso, Piercarlo Saletti, Miriam Martini, Tiziana Cipani, Giovanna Marrapese, Luca Mazzucchelli, Simona Lamba, Silvio Veronese, Milo Frattini, Alberto Bardelli, Salvatore Siena
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2009-10-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC2750753?pdf=render

Internet

http://europepmc.org/articles/PMC2750753?pdf=render

Similar Items